A Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset
5. August 2026 aktualisiert von: JunZhang, Beijing Friendship Hospital
Establishing an Innovative Cohort of Chinese Patients With Gastroesophageal Reflux Disease Based on the Prospective Database of the National Clinical Research Center for Digestive Diseases: A Retrospective Study
This retrospective, observational cohort study aimed to establish a comprehensive research cohort utilizing a large-scale prospective clinical registry.
The primary objectives were to characterize the real-world demographic profiles, clinical features, psychological characteristics, and treatment patterns of Chinese patients with gastroesophageal reflux disease (GERD), as well as to evaluate post-treatment improvements in both GERD symptoms and psychological well-being.
The study retrospectively enrolled approximately 5,000 patients with a confirmed diagnosis of GERD, with data derived from the prospective registry of the National Clinical Research Center for Digestive Diseases.
Investigators systematically extracted data on baseline demographics, clinical presentations, objective diagnostic findings, preoperative psychological status, surgical complications, and longitudinal follow-up outcomes for all eligible patients.
Ultimately, this study sought to provide high-quality, China-specific evidence to inform the precise phenotyping of GERD and to guide standardized, individualized clinical decision-making.
Studienübersicht
Status
Rekrutierung
Bedingungen
Intervention / Behandlung
Studientyp
Beobachtungs
Einschreibung (Geschätzt)
5000
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Zhi zheng, Attending surgon
- Telefonnummer: +86-13811132175
- E-Mail: zhengzhi@ccmu.edu.cn
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100050
- Rekrutierung
- Beijing Friendship hospital, Capital Medical University
-
Kontakt:
- Zhi zheng, Attending surgon
- Telefonnummer: +86-13811132175
- E-Mail: zhengzhi@ccmu.edu.cn
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
The study population will be drawn from the clinical registry of the National Clinical Research Center for Digestive Diseases at Beijing Friendship Hospital, Capital Medical University.
This retrospective cohort study will enroll approximately 5,000 patients with a confirmed diagnosis of gastroesophageal reflux disease (GERD).
During the study period, all eligible patients documented in the registry who meet the inclusion criteria will be consecutively enrolled.
The source population comprises patients presenting to Beijing Friendship Hospital for the diagnosis and management of GERD.
This registry encompasses comprehensive data on clinical symptoms, objective diagnostic findings, treatment details, and longitudinal follow-up outcomes for all enrolled individuals.
As Beijing Friendship Hospital is a major tertiary referral center in China serving a broad geographical catchment area, the study cohort is anticipated to be highly representative of diverse patient demographics and clinical
Beschreibung
Inclusion Criteria:
- Aged between 18 and 90 years old.
- Patients were required to present with at least one typical symptom of gastroesophageal reflux disease (GERD)-such as heartburn, regurgitation, or non-cardiac chest pain-and to have presented to Beijing Friendship Hospital for the evaluation and management of these symptoms.
- Received treatment, including pharmacological therapy and anti-reflux surgery, at Beijing Friendship Hospital.
- Voluntary signing of informed consent, agreeing to the use of clinical information for future research.
Exclusion Criteria:
- Female patients who were pregnant or lactating.
- Patients with significantly incomplete or missing critical clinical data.
- Patients with an equivocal or unconfirmed diagnosis of GERD.
- Current neurologic or cognitive impairment, which would preclude ability to obtain informed consent.
- Refusal to participate in the study.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
GERD Retrospective Cohort
A retrospective cohort of approximately 5,000 patients with a confirmed diagnosis of gastroesophageal reflux disease (GERD) treated at Beijing Friendship Hospital was established using data extracted from the prospective clinical registry of the National Clinical Research Center for Digestive Diseases.
|
Data on clinical symptoms, treatment details, and long-term follow-up outcomes were retrospectively extracted from electronic medical records (EMRs) and institutional databases.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pre- and Post-Treatment Improvement in GERD-HRQL Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) questionnaire is utilized to assess patient outcomes as a quantitative variable.
The scale comprises 11 items, each scored from 0 to 5, with higher scores indicating a better quality of life (QoL).
Clinical success is defined as a >50% reduction in the total symptom score.
|
From pre-treatment to up to 10 years post-treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Helicobacter pylori Infection Status
Zeitfenster: From 30 days prior to surgery to 10 years post-surgery
|
Helicobacter pylori infection status determined by ¹³C/¹⁴C urea breath test.
|
From 30 days prior to surgery to 10 years post-surgery
|
|
Pre- and Post-Treatment Improvement in GERD-Q Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The Gastroesophageal Reflux Disease Questionnaire (GERD-Q) is utilized to evaluate GERD symptoms.
The total score ranges from 0 to 18, with higher scores indicating greater symptom severity.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in GSAS Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The GERD Symptom Assessment Scale (GSAS) is employed to evaluate GERD symptoms.
The total score ranges from 0 to 45, with higher scores indicating greater symptom severity.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in GIQLI Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The Gastrointestinal Quality of Life Index (GIQLI) is utilized to assess quality of life in patients with gastrointestinal diseases.
It comprises five subscales with a total score ranging from 0 to 144.
Higher scores indicate a better quality of life and superior therapeutic efficacy.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in EHAS Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The Esophageal Hypervigilance and Anxiety Scale (EHAS) is utilized to assess esophageal-specific hypervigilance and anxiety.
It comprises two subscales with a total score ranging from 0 to 56, with higher scores indicating more severe esophageal hypervigilance and anxiety.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in HADS Scores
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The Hospital Anxiety and Depression Scale (HADS) is employed to evaluate patient anxiety and depression.
It comprises two subscales with a total score ranging from 0 to 42, with higher scores indicating more severe states of anxiety and depression.
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagitis Severity
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy according to the Los Angeles (LA) classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Severity of Hiatal Hernia
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy according to the Hill classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Presence of Barrett's Esophagus
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy.
|
From pre-treatment to up to 10 years post-treatment
|
|
Acid Exposure Time (AET)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Quantified via pH-impedance monitoring.
AET serves as the primary and most reliable metric for diagnosing objective GERD and evaluating the true burden of acid reflux, >4% indicate abnormal acid reflux
|
From pre-treatment to up to 10 years post-treatment
|
|
Number of Reflux Episodes
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Quantified via pH-impedance monitoring.
|
From pre-treatment to up to 10 years post-treatment
|
|
DeMeester Score
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
The DeMeester Composite Score quantifies the severity of Gastroesophageal Reflux Disease (GERD).
It is calculated from 24-hour ambulatory esophageal pH monitoring using six acid exposure parameters: percentage of total, upright, and supine time with pH < 4; total reflux episodes; episodes lasting > 5 minutes; and the duration of the longest episode.
Each parameter is scored using the formula SV = (X - A) / SD + 1, where X is the measured value, A is the healthy baseline mean, and SD is the baseline standard deviation.
The total score is the sum of these six values.
Minimum value: 0. Maximum value: No fixed upper limit (unbounded).
In clinical applications, higher scores indicate more severe pathological acid exposure.
|
From pre-treatment to up to 10 years post-treatment
|
|
Symptom Index (SI)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Derived from pH-impedance monitoring to determine the temporal correlation between symptom events and reflux episodes, confirming whether a patient's symptoms are specifically reflux-driven.
An SI of ≥ 50% is universally considered positive, indicating a clinically meaningful symptom-reflux association.
|
From pre-treatment to up to 10 years post-treatment
|
|
Symptom Reflux Index (SRI)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Derived from pH-impedance monitoring to provide statistical validation of the symptom-reflux association, which is crucial for accurately phenotyping functional versus organic GERD.
An SRI of ≥ 95% (often utilized interchangeably with Symptom Association Probability, SAP) is considered positive, providing strong statistical evidence that symptoms are not occurring by chance.
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagogastric Junction (EGJ) Expiratory Pressure
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Integrated Relaxation Pressure (IRP)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagogastric Junction (EGJ) Morphology
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via high-resolution manometry (HRM) to assess hiatal hernia status.
|
From pre-treatment to up to 10 years post-treatment
|
|
Distal Latency (DL)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Distal Contractile Integral (DCI)
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophageal Motility Type
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via high-resolution manometry (HRM) according to the Chicago classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Hiatal Hernia Size
Zeitfenster: From pre-treatment to up to 10 years post-treatment
|
Evaluated via computed tomography (CT).
|
From pre-treatment to up to 10 years post-treatment
|
|
Acid-Suppressive Medication Regimen
Zeitfenster: From enrollment to the end of treatment, assessed up to 12 weeks
|
This encompasses the specific medication name, prescribed dosage, and administration frequency.
|
From enrollment to the end of treatment, assessed up to 12 weeks
|
|
Operation Time
Zeitfenster: At the time of surgery
|
At the time of surgery
|
|
|
Blood Loss
Zeitfenster: At the time of surgery
|
At the time of surgery
|
|
|
Abdominal Drainage Fluid Volume
Zeitfenster: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
|
|
Total Duration of Hospitalization
Zeitfenster: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
|
|
Incidence of Postoperative Complications
Zeitfenster: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
17. April 2026
Primärer Abschluss (Geschätzt)
1. April 2027
Studienabschluss (Geschätzt)
1. Mai 2027
Studienanmeldedaten
Zuerst eingereicht
31. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
5. August 2026
Zuerst gepostet (Tatsächlich)
6. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
6. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
5. August 2026
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026-P2-209-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .